METHODS: Serum SARS-CoV-2 specific antibody levels were assessed using enzyme-linked-immunosorbent-assay. Univariate and multivariate binary logistic regression analyses were conducted to identify factors associated with the magnitude of specific humoral immunity and susceptibility to re-infection by XBB variants.
RESULTS: Our data demonstrates that SARS-CoV-2 specific antibody levels were comparable between BA.5-RNPC patients and BA.5 infection-recovered-non-cancerous (BA.5-RNC) individuals. Specifically, serum levels of anti-ancestral-S1-IgG, anti-ancestral-nucleocapsid-protein (NP)-IgG, anti-BA.5-receptor binding domain (RBD)-IgG and anti-XBB.1.1.6-RBD-IgG were higher in BA.5-RNPC patients compared to those without a prior infection. Compared to BA.5-RNPC patients without vaccination, individuals who received inactivated vaccination exhibited significantly higher levels of anti-ancestral-S1-IgG and anti-XBB.1.16-RBD-IgG. Multivariate logistic regression analysis revealed that inactivated vaccination was the most significant predictor of all tested SARS-CoV-2 specific antibodies response. Subsequent analysis indicated that a low globulin level is an independent risk factor for XBB re-infection in BA.5-RNPC patients.
CONCLUSIONS: The SARS-CoV-2 specific antibodies have been improved in vaccinated BA.5-RNPC patients. However, the baseline immunity status biomarker IgG is an indicators of XBB variant re-infection risk in BA.5-RNPC patients.
方法:使用酶联免疫吸附法评估血清SARS-CoV-2特异性抗体水平。进行了单变量和多变量二元逻辑回归分析,以确定与特异性体液免疫强度和XBB变体再感染易感性相关的因素。
结果:我们的数据表明,SARS-CoV-2特异性抗体水平在BA.5-RNPC患者和BA.5感染恢复的非癌(BA.5-RNC)个体之间相当。具体来说,抗祖先S1-IgG的血清水平,抗祖先核衣壳蛋白(NP)-IgG,与之前没有感染的患者相比,BA.5-RNPC患者的抗BA.5-受体结合域(RBD)-IgG和抗XB.1.1.6-RBD-IgG较高.与未接种疫苗的BA.5-RNPC患者相比,接受灭活疫苗接种的个体显示出抗祖先S1-IgG和抗XBB.1.16-RBD-IgG水平显著较高.多变量逻辑回归分析显示,灭活疫苗接种是所有测试的SARS-CoV-2特异性抗体反应的最重要预测因子。随后的分析表明,低球蛋白水平是BA.5-RNPC患者XBB再感染的独立危险因素。
结论:在接种BA.5-RNPC的患者中,SARS-CoV-2特异性抗体得到了改善。然而,基线免疫状态生物标志物IgG是BA5-RNPC患者XBB变异体再感染风险的指标.